in a controlled, but not randomized, cohort study we compared the comprehensiveness of the diagnostic pathway in patients with asthma or COPD before (2013) and after (2015) the implementation period of the diagnostic pathway at the pulmonology outpatient clinic, Franciscus Gasthuis, Rotterdam, the Netherlands.
During the implementation of the pathway, the most recent national guidelines (7-9) were disseminated nationwide. Therefore, quality of healthcare is expected to increase over time in all hospitals regardless of the implementation of the new pathway. To adjust for this phenomenon, we compared our outcomes with the metadata of two control hospitals (2016) that did not implement the pathway but adopted general (inter)national services concerning integrated care of Asthma (1, 13) and COPD (2, 8). These two control hospitals, in the north and south-west of the Netherlands, are comparable to the intervention hospital with respect to their focus on obstructive airways disease and participation in similar (nationwide) projects to improve care for COPD patients.
- Novel items of the Diagnostic pathway
The diagnostic care pathway was based on the Dutch standards of care for patients with Asthma and COPD as described by the Dutch Lung Alliance (LAN) (7, 8). These guidelines are in agreement with international guidelines, especially the assessment of patients with asthma and COPD. These care standards are based on a four-domain model : physiological impairment, symptoms, functional impairment and quality of life (see Figure 1). A two-day stepped diagnostic pathway was made, creating a structured holistic approach, using the domains and diagnostic items in Figure 1 as standardized measurements (10). Three major innovations were added to the existing domains and diagnostic items. Firstly, the metronome-paced hyperventilation test to measure dynamic hyperinflation. Secondly, a physical activity monitor to objectively evaluate physical activity in daily life during seven days. Thirdly, the Nijmegen Clinical Screening Instrument as standardised survey (14). This in-depth view helps to identify individual treatable traits and motivate patients to change their behaviour.
Earlier secondary care studies of obstructive lung diseases had highly specific selection criteria, which made it difficult to extrapolate the results to a large ‘real life’ population (15). We therefore choose to include all patients with suspected asthma, COPD or Asthma-COPD Overlap (ACO). The electronic medical records of all new patients referred by the general practitioner with probable asthma, COPD or ACO were identified six months before (January-June 2013) and one and a half year after (January-June 2015) the implementation of the diagnostic care pathway. Patients with incorrect referral (defined as not referred for diagnoses and treatment of OLD), patients that had been diagnosed previously or patients who visited the pulmonologist for another reason, such as pre-operative assessment or monitoring after hospital admission were excluded.
For each period, 100 medical records of patients referred to the outpatient clinic were selected by an independent researcher using a random number generator.
In the two control hospitals, medical records of patients diagnosed with asthma, COPD or ACO in the period January-June 2016 were analysed. In those control hospitals, medical records were grouped per pulmonologist and every fifth medical record was analysed. The numbers of records analysed are shown in Figure 2.
In the intervention hospital data was collected by a research physician assistant (research-PA). In the control hospitals the data was collected by a research nurse specialist (research-NS). To minimalize differences between data collectors, a data protocol was made, describing the definitions of all variables, called Integral Practice Analyses Trajectory in secondary care (IPAT-2) after which the inter-rater agreement was assessed. In both intervention and control hospitals 50 randomly selected cases were assessed by either research-PA or research-NS and an independent researcher.
Figure 2.
- Characteristics of data registry
Table 2 shows that in the period before implementation of the diagnostic pathway (e.g. 2013), 476 patients had been referred to the pulmonologist suspected for asthma and COPD. After the implementation (2015) the number of referred patients was 413. After applying the in- and exclusion criteria 101 medical records from 2013, divided over five different pulmonologists, were randomly chosen to be included. In 2015 93 patients met the inclusion criteria; they were all included.
In the control hospitals every fifth patient with suspected OLD was selected by the administrative department, resulting in the inclusion of 50 and 57 medical records from the two control hospitals.
To study the feasibility of the pathway we determined the percentage of patients succesfully completing the program.
We assessed the level of implementation in two steps: we calculated the number of items assessed per patient (as an indicator of the level of implementation) and the number of patients assessed per item (as an indicator of which items were poorly implemented) This provides two indicators for the level of implementation.
- Statistics
- Analysis of the test-retest study
Data of research-PA and research-NS were compared using the data of the independent researcher to correct for differences between the hospitals. Cohen’s Kappa was used to measure inter-observer agreement.
The number of diagnostic items assessed per patient was calculated and compared between the diagnostic care pathway group (2015) and baseline (2013) using the Mann-Whitney U Test and the Fisher’s Exact Test.
The percentage of patients per individual diagnostic item (Figure 1) was assessed descriptively and no statistical testing was performed with this data.
To adjust for national trends concerning quality of healthcare, we used data of two hospitals as controls. These hospitals generously provided meta-data and means. Because we had no raw data, medians or other summarizing data could not be calculated. The group included in the care pathway (2015) was compared to the control hospitals (2016) using the one-sample Student’s t-test.
The Medical Research Ethics Committee TWOR declared that this study has no conflict with the Medical Research Involving Human Subjects Act (in Dutch called ‘WMO’) and gave a waiver that neither medical ethical approval nor written informed consent from participants was needed for this registry-based study.